Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

DOP013: Definition of therapeutic response criteria using MRI in Crohn’s Disease patients treated with anti-TNF therapy: A multicenter prospective study (the IRMA study)ECCO'17 Barcelona
Year: 2017
Authors: Buisson A.
Crohn's disease, Disease activity Indices, MRI, Adalimumab, Infliximab
Files: 1
DOP014: Transmural healing is better than mucosal healing in Crohn's DiseaseECCO'17 Barcelona
Year: 2017
Authors: Raimundo Fernandes S.
Natural history, Colonoscopy, MRI
Files: 1
DOP015: International differences in gastroenterologists’ perspective on stopping therapy for patients with Crohn’s DiseaseECCO'17 Barcelona
Year: 2017
Authors: Siegel C.
Anti-TNF agents, Corticosteriods, Patient choice, Thiopurines (AZA / MP)
Files: 1
DOP017: Patterns of anti-TNF use and associated treatment outcomes in Inflammatory Bowel Disease patients: Results from an analysis of Dutch health insurance claims dataECCO'17 Barcelona
Year: 2017
Authors: Bots S.
Health economic analysis, Adalimumab, Anti-TNF agents, Infliximab
Files: 1
DOP018: Effect of adalimumab on extraintestinal manifestations among patients with Ulcerative Colitis in a clinical practice setting: Results from INSPIRADAECCO'17 Barcelona
Year: 2017
Authors: Skup M.
Adalimumab, Arthralgia, Pyoderma gangrenosum, Other extraintestinal manifestations
Files: 1
DOP019: Effect of vedolizumab treatment on extraintestinal manifestations in patients with Crohn’s Disease: A GEMINI 2 post hoc analysisECCO'17 Barcelona
Year: 2017
Authors: Feagan B.
Crohn's disease, Vedolizumab, Other extraintestinal manifestations
Files: 1
DOP020: Higher vedolizumab levels are associated with deep remission in patients with Crohn’s Disease and Ulcerative Colitis on maintenance therapy with vedolizumabECCO'17 Barcelona
Year: 2017
Authors: Yarur A.
Patient reported outcomes, Therapeutic drug monotoring, Pharmacokinetics, Treat to tatrget, Vedolizumab
Files: 1
DOP022: Vedolizumab (VDZ) and anti-α treatment effectiveness in patients with IBD treated in Germany: A retrospective chart reviewECCO'17 Barcelona
Year: 2017
Authors: Ehehalt R.
Crohn's disease, Anti-TNF agents,Vedolizumab
Files: 1
DOP024: Vedolizumab clinical and post-marketing safety experience of opportunistic infectionsECCO'17 Barcelona
Year: 2017
Authors: Ng S.
Concomitant infections, Vedolizumab
Files: 1
DOP025: Efficacy of vedolizumab on extraintestinal manifestation in patients with Inflammatory Bowel Disease: A post-hoc analysis of the OBSERV-IBD cohort from the GETAIDECCO'17 Barcelona
Year: 2017
Authors: Tadbiri S.
Vedolizumab, Arthralgia, Perianal disease, other extraintestinal manifestations
Files: 1
DOP027: Long-term efficacy and safety of ustekinumab in refractory Crohn’s Disease patients: A multicenter retrospective experienceECCO'17 Barcelona
Year: 2017
Authors: Wils P.
Crohn's disease, Anti-TNF agents, Ustekinumab
Files: 1
DOP028: Antibodies towards vedolizumab appear from week 2 onwards and disappear upon treatmentECCO'17 Barcelona
Year: 2017
Authors: Bian S.
Anti drug antibodies, Vedolizumab, Immunology
Files: 1
DOP029: Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: Post-hoc analysis of the taxit trialECCO'17 Barcelona
Year: 2017
Authors: Van Stappen T.
Crohn's disease, Ulcerative colitis, Anti-TNF drug levels, Anti drug antibodies, Therapeutic drug monitoring, Infliximab
Files: 1
DOP031: Subtherapeutic serum infliximab trough levels and complete mucosal healing are associated with sustained clinical remission after infliximab discontinuation in paediatric Crohn’s Disease patientsECCO'17 Barcelona
Year: 2017
Authors: Kang B.
Anti-TNF drug levels, Colonoscopy, Infliximab, Pharmacokinetics, Thiopurines (AZA / MP)
Files: 1
DOP032: Hydrocortisone premedication withdrawal in patients on stable infliximab maintenance: Clinical and pharmacokinetic outcomesECCO'17 Barcelona
Year: 2017
Authors: Tran-Minh M.
Anti-TNF drug levels, Anti-drug antibodies, Anti-TNF agents, Infliximab
Files: 1